Trials / Completed
CompletedNCT04061044
A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert
A Prospective, Multicenter, Open Label Extension Study to Evaluate the Long Term Safety of OTX-TP
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Ocular Therapeutix, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the long term safety of repeat dose OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle glaucoma or ocular hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ophthalmic Insert | Travoprost, 0.32 mg |
Timeline
- Start date
- 2018-07-10
- Primary completion
- 2020-02-10
- Completion
- 2020-09-22
- First posted
- 2019-08-19
- Last updated
- 2023-06-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04061044. Inclusion in this directory is not an endorsement.